ArticleEuropean journal of immunology2021
High seroprevalence but short-lived immune response to SARS-CoV-2 infection in Paris.
Article in European journal of immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04369066 (COVID-19 Study of the Serological Response Against the SARS-CoV-2 Virus in 2 Types of Employees, Hospital and Non-hospital, at Institute Curie and Institute Pasteur), which is not on this map. Cited by 45 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
COVID-19 Study of the Serological Response Against the SARS-CoV-2 Virus in 2 Types of Employees, Hospital and Non-hospital, at Institute Curie and Institute Pasteur
Who cites it
45 citing papers in PubMed, 3 syntheses or guidelines pooled it, 66 citations in OpenAlex.
- Pooled it
- Taste loss as a distinct symptom of COVID-19: a systematic review and meta-analysis.Chemical senses · 2023Pooled it
- SARS-CoV-2 seroprevalence around the world: an updated systematic review and meta-analysis.European journal of medical research · 2022Pooled it
- Risk factors for acquisition of SARS-CoV-2 Omicron variant among a prospective cohort of French Healthcare Workers: impact of hybrid immunity.Scientific reports · 2026Article
- mRNA COVID-19 vaccination induces minimal IgA in saliva in the absence of prior clinical or subclinical infection.Vaccine · 2026Article
- Household exposure, demographic and health characteristics associated with SARS-CoV-2 infection in a cohort study in Northern France.Scientific reports · 2025Article
- Fluke-borne viruses are a risk factor for diseases caused by carcinogenic trematodes.bioRxiv : the preprint server for biology · 2025Article
- Longitudinal analysis of passively and actively acquired SARS-CoV-2 antibodies in infants with repeat newborn screening samples.Scientific reports · 2025Article
- Viruses of parasites: A roadmap toward diagnostic and therapeutic development.PLoS neglected tropical diseases · 2025Review
- A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: candidate selection in a preclinical murine model.Journal of virology · 2024Article
- Application of Machine Learning Prediction of Individual SARS-CoV-2 Vaccination and Infection Status to the French Serosurveillance Survey From March 2020 to 2022: Cross-Sectional Study.JMIR public health and surveillance · 2023Article
- One-Year Follow-Up of Seroprevalence of SARS-CoV-2 Infection and Anxiety among Health Workers of a French Cancer Center: The PRO-SERO-COV Study.International journal of environmental research and public health · 2023Article
- Article
- Article
- Article
- Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community-based, prospective, longitudinal cohort study.EClinicalMedicine · 2022Article
- COVID-19 disease and autoimmune disorders: A mutual pathway.World journal of methodology · 2022Review
- Potent human broadly SARS-CoV-2-neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2.The Journal of experimental medicine · 2022Article
- Prevalence and determinants of SARS-CoV-2 neutralizing antibodies in Lebanon.Archives of virology · 2022Article
- Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network.The Journal of infection · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although the COVID-19 pandemic peaked in March/April 2020 in France, the prevalence of infection is barely known. Using high-throughput methods, we assessed herein the serological response against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) of 1847 participants working in three sites of an institution in Paris conurbation. In May-July 2020, 11% (95% confidence interval [CI]: 9.7-12.6) of serums were positive for IgG against the SARS-CoV-2 N and S proteins, and 9.5% (95% CI: 8.2-11.0) were neutralizer in pseudo-typed virus assays. The prevalence of seroconversion was 11.6% (95% CI: 10.2-13.2) when considering positivity in at least one assay. In 5% of RT-qPCR positive individuals, no systemic IgGs were detected. Among immune individuals, 21% had been asymptomatic. Anosmia (loss of smell) and ageusia (loss of taste) occurred in 52% of the IgG-positive individuals and in 3% of the negative ones. In contrast, 30% of the anosmia-ageusia cases were seronegative, suggesting that the true prevalence of infection may have reached 16.6%. In sera obtained 4-8 weeks after the first sampling, anti-N and anti-S IgG titers and neutralization activity in pseudo-virus assay declined by 31%, 17%, and 53%, resulting thus in half-life of 35, 87, and 28 days, respectively. The population studied is representative of active workers in Paris. The short lifespan of the serological systemic responses suggests an underestimation of the true prevalence of infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.